Illumina Signs Genotyping Services Agreement With Placer, LLC
BeadArray Technology To Help Correlate SNP Genotypes with Psoriasis and Related Dermatological Conditions
SAN DIEGO--(BW HealthWire)--May 2, 2002--Illumina, Inc. announced today that it has signed a commercial agreement with Placer, LLC, a privately held biotechnology firm, to provide single nucleotide polymorphism (SNP) genotyping services on a sample collection provided by Placer. Under the terms of the agreement, Illumina will use its BeadArray(TM) technology to genotype specified SNPs in the sample set. Illumina will also design functional assays for the SNP loci, which are believed to be associated with psoriasis and other common skin conditions. Further details about the agreement were not disclosed.
Jay Flatley, Illumina President & CEO, noted, "Placer is focusing its development efforts on understanding genes whose polymorphisms confer susceptibility or resistance to complex heritable diseases. Psoriasis is the first such disease to be studied by Placer, and we're pleased that they have elected to work with our BeadArray platform. Illumina's genotyping services offer industry-leading sample throughput and unparalleled multiplex levels -- critical factors in the accelerated understanding of genetic variation and function."
Illumina (Nasdaq: ILMN; www.illumina.com) is developing next-generation tools that permit large-scale analysis of genetic variation and function. The Company's proprietary BeadArray(TM) technology provides the throughput, cost effectiveness and flexibility necessary to enable researchers in the life sciences and pharmaceutical industries to perform the billions of tests necessary to extract medically valuable information from advances in genomics and proteomics. Illumina's technology will have applicability across a wide variety of industries beyond life sciences and pharmaceuticals, including agriculture, food, chemicals and petrochemicals. |
